Privo Technologies
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
200 Corporate Pl Ste 6B, Peabody, Massac...Phone Number
(978) 587-2322Website
www.privotechnologies.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Privo Technologies
Privo Technologies, Inc. is dedicated to developing innovative therapeutics aimed at eliminating cancers and preventing recurrence, with a focus on providing accessible treatment options for diverse patient populations. Their PRV platform technology offers targeted therapies that minimize systemic toxicity, with formulations including topical patches and intratumoral injectables for various cancer types. The company is currently advancing multiple products through clinical trials, including PRV111 for head and neck cancer and PRV211 for intraoperative chemotherapy. Privo collaborates with institutions like the FDA and NCI, having secured over $20 million in funding to support its research and development efforts.Explore more
Privo Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Privo Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Privo Technologies
Product Launch: Get notified when Privo Technologies launches new products
Earning: See what the market has to say on Privo Technologies recently announced quarterly report
Check out if Privo Technologies is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Privo Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Privo Technologies has recently received funding, and reach out quickly before it becomes old news!
Click to see if Privo Technologies had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Privo Technologies has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Privo Technologies as Masked Content
Find more new buyers
Compare Similar Companies to Privo Technologies
Compare insights from companies similar to Privo Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Privo Technologies
<$5M
1-10
Private
-
2009
AM
Aaron ManziSenior Director, Research, Development & Manufacturing
Company Profile Activity
Activity Insights
Privo Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Privo Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Privo Technologies.
Privo Technologies Tech Stack
A closer look at the technologies used by Privo Technologies
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Project
Spending/Investment, Funding
Funding
Project
received an award of $987,292 on April 1, 2023 by HHS NIH with an award end date of March 31, 2025. This award will support efforts focused on advancing Privo's PRV211, a nano-engineered hydrogel for local delivery of immuno/chemotherapy nanoparticles, aiming to enhance locoregional control and reduce recurrence in advanced oral squamous cell carcinoma..
Clinical Operations, Operations
Executive Move
Board of Directors
Privo Technologies News & Media
Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer
Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo's PRV Platform technology, PRV131 delivers high concentrations of cisplatin directly to tumors, while minimizing systemic exposure. BOSTON, Mass., Dec....PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial
Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a single cycle of PRV111; the remaining patient was down-staged from high-grade to low-grade dysplasia. All patients avoided surgery: PRV111 cleared...Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery
PEABODY, Mass., Oct. 14, 2025 /PRNewswire/ -- Privo Technologies, Inc. ("Privo" or "the Company"), a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating...Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers
PEABODY, Mass., April 28, 2025 /PRNewswire/ -- Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier clinical sites across the United States for its ongoing CLN-004...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Privo Technologies
Sign Up For FreeTo access detailed company insights
Privo Technologies, Inc. is dedicated to developing innovative therapeutics aimed at eliminating cancers and preventing recurrence, with a focus on providing accessible treatment options for diverse patient populations. Their PRV platform technology offers targeted therapies that minimize systemic toxicity, with formulations including topical patch... Read More
